Exodus Point Capital Management, LP Selecta Biosciences Inc Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$1.15 - $1.89 $27,599 - $45,360	24,000 New	24,000 $33,000
Q2 2022 Aug 19, 2022	SELL	$0.67 - $1.4 $8,688 - $18,155	-12,968 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.23 - $3.31 $2,431 - $6,543	-1,977 Reduced 13.23%	12,968 $16,000
Q4 2021 Feb 11, 2022	SELL	$2.89 - $4.43 $20,007 - $30,668	-6,923 Reduced 31.66%	14,945 $49,000
Q3 2021 Nov 15, 2021	BUY	$3.36 - $4.62 $73,476 - $101,030	21,868 New	21,868 $91,000
Q2 2021 Aug 16, 2021	SELL	$2.82 - $5.01 $55,745 - $99,037	-19,768 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$2.92 - $5.07 $16,936 - $29,406	-5,800 Reduced 22.68%	19,768 $89,000
Q4 2020 Feb 16, 2021	BUY	$1.64 - $3.42 $41,931 - $87,442	25,568 New	25,568 $77,000
Q2 2020 Aug 14, 2020	SELL	$1.83 - $4.06 $59,109 - $131,138	-32,300 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.5 - $4.52 $27,789 - $83,737	18,526 Added 134.5%	32,300 $78,000
Q4 2019 Feb 14, 2020	BUY	$1.32 - $2.47 $18,181 - $34,021	13,774 New	13,774 $33,000

4.67M

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.